Crohn’s Disease – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Crohn’s Disease Emerging Therapy and TPP Insights

Thelansis’s “Crohn’s Disease Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Crohn’s Disease Overview

Crohn’s disease is a chronic, relapsing inflammatory bowel disease that can affect any part of the gastrointestinal tract, often with patchy, transmural inflammation. It may cause abdominal pain, diarrhea, fatigue, and weight loss; complications include strictures, fistulas, abscesses, and malnutrition. Its causes involve genetic susceptibility, immune dysregulation, gut microbes, and environmental factors. Treatment depends on disease location, severity, and complications. Corticosteroids may induce remission but are unsuitable for long-term maintenance. Advanced options include anti-TNF agents, gut-selective vedolizumab, IL-12/23 or IL-23 inhibitors, and the oral JAK1 inhibitor upadacitinib. Nutritional support, smoking cessation, monitoring, and surgery for selected complications also have a role. Despite broader treatment choices, some patients have incomplete responses, lose response, or develop bowel damage, sustaining the need for durable, individualized disease control.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)